Management of Malignant Gliomas continues to be a challenge. We prospectively studied the role of adding weekly Paclitaxel to Fractionated Stereotactic Radiation Therapy (FSRT) in the treatment of Malignant Gliomas. Twenty-three Glioblastoma Multiforme and two Anaplastic Astrocytoma were studied. Patients received 46 Gy at 2 Gy/fraction followed by a boost utilizing FSRT at a fraction of 2.5 Gy for 8 fractions. Paclitaxel is delivered concomitantly at 150 mg/m 2 weekly for six cycles. Eighteen patients had pharmacokinetic assays of Paclitaxel levels. All patients were followed until death or for a maximum of 36 months. The overall survival of the whole group was 14 months. The median survival for RPA prognostic classes III, IV, V, and VI were 20, 14, 12, and 11 months. Higher survival (14 months) was noted in the subtherapeutic phenytoin level group compared to 10 months in the therapeutic group (P=0.271). No grade 4 CTCAE (version 3.0) toxicities were observed. Enhanced survival was demonstrated with gross tumor resection (20.8 months), KPS ≥80 (18.7 months) and age ≤60 years (27 months) as compared to subtotal resection or biopsy (12.1 months, P< 0.005), KPS ≤70 (10.8 months, P=0. 005) and older age > 60 (10.46 months, P=0.006),
Introduction
Malignant Gliomas are the most common of all CNS tumors. Treatment options include surgical resection, radiation therapy, and chemotherapy. Survival results continue to be poor with median survival generally in the 9-or 10-month range (1-6). The effectiveness of radiation therapy in terms of a survival benefit was demonstrated in prospective randomized studies (1, 2, 7, 8) . A dose response relationship was suggested with doses of ≤60 Gy (7) . However, the Radiation Therapy Oncology Group (RTOG)/Eastern Cooperative Oncology Group (ECOG) study with an additional boost of 10 Gy to a total dose of 70 Gy in a large volume did not result in further improvement of survival (5).The main pattern of failure is local, and local control of high-grade glioma may be achieved by increasing the dose to the tumor without increasing the dose to normal brain tissue.
Focal radiotherapy has been used in the treatment of recurrent gliomas or as a boost in the initial management with encouraging preliminary results. It Technology in Cancer Research & Treatment, Volume 6, Number 3, June 2007 was administered by interstitial brachytherapy (IRT) (9-12), as Stereotactic radiation therapy (SRT) (13, 14) , as radiosurgery (SRS) (18) (19) (20) , or as an integrated boost with intensity-modulated radiotherapy (21) . Radiosurgery carries an increased risk of radiation necrosis because of its inherent large fraction size (22) . Published data suggest that Fractionated Stereotactic Radiotherapy (FSRT) is associated with a lower incidence of necrosis compared with SRT (14, 23, 25, 26) . FSRT combines the radiobiological advantages of reducing normal tissue toxicities and precise focal dose delivery (27) (28) (29) (30) .
Several chemotherapeutics have been employed in the management of malignant gliomas. Both radiosensitizer and cytotoxic agents were utilized with variable degrees of success. BCNU (31), Paclitaxel (32), Thalidomide (33), Temozolamide (34, 43) are among the agents studied in this disease.
The use of TMZ with radiation therapy was strengthened by the Stupp study (43) with an overall survival of 14.6 months (mo) compared to 12.1 mo for radiation therapy alone. However, 53% of patients discontinued adjuvant TMZ because of disease progression and/or toxicity.
This prospective study was conducted to assess the value of FSRT boost after conventional radiation therapy in addition to weekly outpatient 3-hour infusion of Paclitaxel with respect to survival and toxicity in the initial management of patients with malignant glioma. The survival outcomes were also compared to other regimens. The Pharmacokinetics study was performed to correlate Paclitaxel levels with final outcome and toxicities.
Study Population
Twenty-five newly diagnosed patients with malignant gliomas were treated on a prospective trial that was approved by the institutional review board.
Eighteen were males and seven were females, age ranges from 34-83 years with a median of 67 years old. Karnofsky performance status ranged from 70-100 (median 70). All patients had pathological diagnosis of malignant gliomas; two had biopsy only, 15 subtotal resection, and eight had gross total resection. The final pathological diagnosis was Glioblastoma Multiforme (GBM) in 23 patients and Anaplastic Astrocytoma (AA) in the remaining two patients. Type and level of anticonvulsants were recorded.
Patient characteristics and distribution according to RTOG prognostic RPA classes (35) are shown in Table I .
Study Design
Treatment was initiated within four weeks of the neurosurgical intervention, after patients met eligibility criteria, signed informed consent, and had a pretreatment volumetric MRI scan to establish the pretreatment volume.
Radiation Therapy
Conventional partial brain irradiation was utilized. PTV was defined as the volume of T2 signal + 2 cm using the preoperative MRI study. 46.0 Gy at 2 Gy/fraction was delivered over 23 treatments in 4.5 weeks.
FSRT Boost
A second planning CT scan with intravenous contrast was performed using a slice thickness and distance of 3 mm. The stereotactic PTV included the pre-operative tumor volume plus a margin of 2 mm based on the pre-operative contrastenhancing region on CT or T1-weighted MR scans. If there was no residual tumor, the operative cavity plus 2 mm was used as the stereotactic PTV.
Relocatable frames were used; Gillman-Thomas-Cosman (GTC) frame was used in 17 patients and Glad-X Laitinin streoadaptor was employed in four patients [commissioning, acceptance, and technique of utility of this frame are published elsewhere (30)]. Dose per fraction was 2.5 Gy daily for 8 fractions delivered to the significant isodose line (Median 80%). 
Chemotherapy
Paclitaxel was administered at a dose of 150mg/m 2 weekly as a 3-hour outpatient infusion. Routine premedications are employed according to standard practices. Routine blood picture was obtained weekly prior to infusion. Total of six cycles were delivered concomitantly with irradiation.
Plasma Paclitaxel Measurement
Blood sampling to determine the paclitaxel concentration versus time profile was performed during the third or fourth treatment cycles. Paclitaxel was given as a 3 h infusion. Ten ml of blood was collected from the arm opposite of that to which the paclitaxel was administered; prior to starting the infusion, and at the 10 minutes, 30 minutes, 1, 2, 3, 6, and 24 hours after the start of paclitaxel infusion. Venous blood was kept cool after procurement and plasma was separated by centrifugation at 1500g for 5 minutes. Aliquots of plasma were then stored at -70 ºC, prior to shipping to the Memorial Sloan Kettering hospital biochemistry laboratory where paclitaxel concentrations were measured using HPLC. Paclitaxel concentrations were assayed using a published high pressure liquid chromatography method (36, 37). The assay was linear over the concentration range 0-2000 ng/ml and the lower limit of detection of the assay was 20 ng/ml (36, 37) . Using this assay, the interday and intraday coefficients of variation over the range of concentrations of the standard curve ranged from 4.1-11.2% and 3.8-9.9%, respectively.
Pharmacokinetic Analysis
The paclitaxel concentrations versus time data were inspected on a semi-logarithmic plot of concentration versus time. The data were analyzed using the WinNonLin version 4.1 (Pharsight Corporation, CA). A non-compartmental analysis with a continuous infusion input (model 202) was used. The terminal 3-5 points of plasma paclitaxel concentration time data for each patient were used to estimate the terminal decay and a linear log trapezoidal method was used to estimate the AUC (0-inf). Pharmacokinetic parameters were computed using standard equations with specific interest in the paclitaxel clearance.
Plasma phenytoin concentrations were measured on the morning of the same day as the paclitaxel concentrations were measured, using Centaur chemiluminescence's assay. All phenytoin concentration measurement points were obtained at trough just prior to the next daily dose of phenytoin.
Statistical Analysis
Survival analyses were estimated using Kaplan-Meier test. Correlations between parameters, e.g., paclitaxel clearance and phenytoin concentrations, was evaluated using an ANO-VA and linear regression analysis.
Results

Tolerance
All patients completed the entire course of treatment. The regimen was well tolerated, no grade 4 CTCAE (version 3.0) toxicities were observed. Grade 2 Leucopenia was encountered in six patients and three had grade 3 necessitating GM-CSF administration. No allergic reactions were seen.
Survival
The median survival of the whole group was 14 months (mo); the median follow up period was 36 mo (95% confidence intervals, 10-15 mo). Figure 1 reflects the overall survival for the whole group. The median survival was classified according to recursive partitioning analysis (RPA) prognostic classes and compared to RTOG RPA published figures. The median survival for RPA prognostic classes III, IV, V, and VI were 20, 14, 12, and 11 mo compared to 17.9, 11.1, 8.9, and 4.6 mo in the RTOG study (Table II) . Figure 2 illustrates survival according to RPA classes.
Determinants of Survival
Overall survival was correlated with age, performance status, and extent of surgical resection. Longer survival was observed in patients younger than 60 years. The median survival was 27.0 months in patients ≤ 60 years compared to 10.46 mo in the older group (P=0.006). Patients with performance status ≥ 80 had median survival of 18.7 mo versus 10.8 mo in those with performance status of < 80 (p=0.005). Patients who underwent gross total resection at presentation had median survival of 20.8 mo compared to 12.1 mo in patients who underwent subtotal resection or biopsy only (P<0.005). Six patients had reoperation (four for recurrent tumor, two for radiation necrosis); their median survival was 17.6 mo compared to 13.5 mo in those with no further reoperation.
Correlation of Survival to Paclitaxel Clearance and Phenytoin Concentrations
Eighteen patients underwent pharmacokinetic studies and survival of patients was correlated with phenytoin concentration ( Figure 3a ). The median survival was 14 months in glioma patients with subtherapeutic phenytoin concentrations (< 10 mg/L) and was 10 months in patients with therapeutic phenytoin concentrations (p=0.27). Figure 3b illustrates the correlation between survival of patients and their corresponding paclitaxel clearance. No significant correlation was observed
Correlation of Paclitaxel Clearance and Phenytoin Level
The scattergram in Figure 4 illustrates the relation between phenytoin concentration and paclitaxel clearance. Al- though the regression line showed inverse correlation, the 2 R value demonstrated high degree of variability which did not reach statistical correlation.
Discussion
Malignant Gliomas are the most common primary brain malignant tumors in adults (25). Glioblastoma Multiforme (GBM) contributes more than 90% of all primary malignant variants with a median survival generally less than 10 mo (1-6). Attempts at improving survival generally utilized escalating dose of radiation and/or addition of various radiosensitizing chemotherapeutics. Radiation therapy (60Gy) ± BCNU results in median survival of 35 weeks and 18 months for GBM and AA, respectively (31). RTOG conducted a study of conventional external radiation therapy and weekly 3-hour infusion of Paclitaxel at a dose of 225 mg/m 2 . The regimen was well tolerated resulting in median survival of 9.7 mo with median survivals for RPA classes III, IV, V, and VI of 17.9, 11.1, 8.9 and 4.6 months (32).
Addition of Temozolomide (TMZ) was reported to increase overall survival by 1.7 months from 24.6 weeks for Procarbazine to 31.9 weeks for TMZ (44). In the Stupp trial (43), there was a significant benefit in the TMZ group with respect to median survival (14.6 months vs. 12.1 months) compared to radiation therapy alone. The median progression-free survival was 6.9 months vs. 5.0 months, and the 2-year overall survival was 26.5% vs. 10.4%. Yung and associates have reported on the benefit of TMZ over Procarbazine, the estimated absolute survival was 60% (95% CI 51 to 70%) for TMZ compared to 44% (95% CI, 35 to 53) for Procarbazine (45).
FSRT couples the advantages of escalating radiation dose and keeping adjacent normal brain tissue doses within acceptable ranges. Davis and associates (38) employed SRT boost of 20 Gy following partial brain irradiation of 60 Gy with no chemotherapy in a group of mainly GBM patients.
The median survival was 20 mo with no significant morbidities. Cho and associates (39) compared in a non-randomized manner SRS to SRT in recurrent high-grade gliomas and observed similar outcome with less morbidity in the fractionated stereotactic group.
In the current study, we employed conventional radiation therapy to 46 Gy and SRT of 2.5 Gy for 8 fractions at a median of 80% isodose line. Using the linear quadratic (LQ) equation (40), a standard RT regimen of 60.0 Gy in daily fractionation over six weeks would yield a BED for late responding tissues of 89-100 Gy and a BED for acutely-responding tissue of 72-75 Gy. Using the same assumptions, the stereotactic fractionation scheme in the present trial results in late responding BED of 113-127 Gy and the BED for acutely-responding tissue would be 80-88 Gy, an increase of 11% in local tissue effect and a similar increase in late tissue effects. However, the latter was not observed because of the relatively smaller volume treated by SRT.
The overall median survival in the current study for the whole group was 14 mo, which is superior to RTOG regimen of Paclitaxel and conventional radiation with no addition of stereotactic boost (32). The median survivals for RPA class III, IV, V, and VI were 20, 14, 12, 11 mo compared to 17.9, 11.1, 8.9, and 4.6 mo, respectively in the RTOG study. The observed median survival rate in this study (14 mo) is superior to the standard arm of radiation therapy alone (12.1 mo) and approaching those of radiation therapy and TMZ in the Stupp trial (14.6 mo) (43). However, due to the small sample size; our data needs to be validated in a higher powered study.
The regimen was well tolerated with no grade 4 toxicities, the treatment was not interrupted for any therapy related sides effects, and furthermore, all patients completed the entire regimen. In Stupp's trial (43), during adjuvant TMZ therapy, 4% of patients had grade 3 or 4 neutropenia, 11% had grade 3 or 4 thrombocytopenia, and severe infections occurred in 5% of patients. Adjuvant TMZ was also discontinued in 53% of patients; either due to disease progression (39%), toxic effects (8%), or other reasons (6%) (43).
Contrasting costs between the two chemotherapeutic regimens, we established a reference surface area of 2 m 2 . The cost of the chemotherapeutic units was determined from Mosby's Drug Consult (46). The cost of 150mg/m 2 of Paclitaxel for six cycles was compared to the cost of adjuvant TMZ (75mg/m 2 ) for 49 days, followed by 150mg/m 2 for the first cycle, then 200mg/m 2 of TMZ for the next five cycles. The overall cost of TMZ was $32,848.21 compared to $17,909.10 for Paclitaxel. The cost of the radiation therapy regimen was purposely not incorporated since it could be used with any chemotherapeutic regimen. The survival rates in our regimen using Paclitaxel are approaching those using TMZ; however, with a much better toxicity profile and at a considerably lower cost. Since both the radiation therapy regimen and chemotherapy regimen in this study are novel, we are not certain which modality(s) is/are responsible for the improved outcome.
Several prognostic factors were found to be significant for survival; namely extent of surgical resection, age, and performance status, which parallels other reports.
The interaction between Paclitaxel and anticonvulsants is probably due to induction of cytochrome P450 mediated hepatic metabolism of paclitaxel specifically via induction of CYP3A (41). In order to clarify the role of this interaction in a clinical setting, Chang and associates (42) reported in a phase II study their experience in recurrent malignant gliomas; patients were stratified to receive two different doses of Paclitaxel based on concomitant use of anticonvulsants. However, despite the increased doses delivered in patients on anticonvulsants there was no significant difference in responses.
In our study, a trend towards enhanced survival (14 mo) was observed in the subtherapeutic phenytoin group compared to 10 mo in the therapeutic group. The four months median survival difference may be due to higher brain tissue concentrations of paclitaxel in this subgroup. Our data suggest it is not due in this study to different exposures to paclitaxel (plasma paclitaxel AUCs in therapeutic versus subtherapeutic phenytoin patients were not statistically different; two tailed unpaired "t" test p=0.1). Other potential confounding factors that maybe contributing to our observations are that the threshold phenytoin concentrations in any one patient that produce CYP and/or P-gp induction are not known and probably vary from patient to patient as does the extent of the induction. Neither is it defined in vivo whether this is a threshold, all or none phenomenon or is it concentration related by the curvilinear sigmoid Emax type of relationship.
These patients were also on corticosteroids, which is another known inducer of CYP3A. Phenytoin induces CYP3A but is not known to induce CYP2C8, the latter is the major CYP involved in paclitaxel metabolism. Chronic phenytoin treatment may induce the amount of MDR-1 (P-gp) or other drug transporters in human brain tissue and this could potentially reduce Paclitaxel concentrations obtained in human brain tissue.
Finally, this study could be underpowered to define relationships between paclitaxel CL and phenytoin if they exist.
Our observations need to be further validated in a larger group of patients.
The same was observed when correlating survival and paclitaxel levels; survival was enhanced with increasing paclitaxel with a trend towards significance (P=0.17). This correlation was not clearly detected probably due to one or more of these reasons: Phenytoin level, which induces enzyme induction is not clearly known, or since the actual brain concentration of paclitaxel was not measured, or because only one out of two enzymes metabolizing paclitaxel is induced by Phenytoin. These observations need to be further validated in a larger group of patients.
Conclusions
The use of FRST and paclitaxel is well tolerated with no significant morbidity. The regimen resulted in improvement of survival of RPA classes IV, V, VI compared to historical studies using this regimen. Higher survival is noted in patients with subtherapeutic Phenytoin levels.
The survival results using this regimen are superior to previous ones utilizing Paclitaxel and approaching those using TMZ. Future studies with Temozolomide may consider incorporating FSRT in their regimens.
